Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 101 participants.

Also called NCT03082014

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 101 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03082014
Other papers using this trial's data
  • Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial The Lancet. Neurology, 2023-11 DOI, PubMed 37863608

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany, Netherlands, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03082014. Randomized; single masking; primary purpose treatment. Start 2018-02-22 (actual); primary completion 2022-07-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function
Acronym
TREAT-SVDs
Condition
Cerebral Small Vessel Diseases
Intervention (Drug)
Amlodipine
Intervention (Drug)
Losartan
Intervention (Drug)
Atenolol
Lead sponsor
Ludwig-Maximilians - University of Munich (class: other)
Collaborator
University of Edinburgh (class: other)
Collaborator
Maastricht University Medical Center (class: other)
Collaborator
UMC Utrecht (class: other)
Collaborator
University of Oxford (class: other)

Record details

Record id
cardio:ct-nct03082014
Content hash
9083df52857d603ad2b879f4b4c65f0495878ebcd38ccad2b48272a5d14bde42